Superpower partnership puts GRAIL’s Galleri test in front of more users
GRAIL (GRAL) shares were in focus after Superpower announced a partnership that gives its members nationwide access to the Galleri multi cancer early detection blood test, which is integrated directly into Superpower’s preventative health platform.
See our latest analysis for GRAIL.
The Superpower partnership landed after a volatile stretch, with a 10.32% 7 day share price return and a 3.01% 30 day share price return contrasting with a 50.24% 90 day share price decline and a 115.81% 1 year total shareholder return. This suggests that momentum has recently started to rebuild from a much lower base.
If this kind of healthcare AI adoption story interests you, it might be worth scanning the wider space and seeing what stands out in the 37 healthcare AI stocks
With GRAIL posting US$147.2m in revenue against a US$408.4m loss and trading around US$51.74, the key question is whether the recent rebound and analyst target of US$72.40 leave upside on the table or if the market is already pricing in future growth.
Most Popular Narrative: 28.5% Undervalued
With GRAIL trading at $51.74 against a narrative fair value of $72.40, the most followed storyline frames the shares as materially discounted, hinging on execution of ambitious growth and margin goals.
Ongoing positive clinical trial results, including substantially higher cancer detection and positive predictive value with consistent specificity for Galleri in population scale studies, are setting the stage for robust FDA approval and broad payer reimbursement, which could unlock significant new revenue streams and accelerate top line growth.
Read the complete narrative. Read the complete narrative.
Want to see what is baked into that gap between fair value and today’s price? Revenue compounding, margin rebuild and a future earnings multiple that leans heavily on Galleri’s long term adoption are all in the mix, but the exact expectations might surprise you.
Result: Fair Value of $72.40 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that gap only holds if key risks stay contained, including the NHS Galleri study missing its primary endpoint and ongoing high cash burn alongside a US$408.4m loss.
Find out about the key risks to this GRAIL narrative.
Another Angle On Valuation
The fair value narrative points to GRAIL as 28.5% undervalued at $72.40, yet the market is already paying a rich P/S of 14.4x. That is more than 3x the estimated fair ratio of 5.1x and well above both peer and industry averages, which raises the question of how much disappointment this pricing can absorb.
Before leaning too heavily on any single fair value number, it can help to see how the current P/S stacks up visually and where the fair ratio suggests the market could move toward over time, especially if sentiment or growth expectations shift away from the current narrative. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
The mix of optimism and caution around GRAIL is clear. Move quickly, review the underlying numbers, and form your own view using the 2 key rewards and 5 important warning signs
Looking for more investment ideas?
If you stop at GRAIL, you could miss other compelling setups. Widen your search and let the data point you toward fresh opportunities.
- Spot potential mispricings early by scanning companies that screen as quality yet are priced for hesitation through the 62 high quality undervalued stocks.
- Prioritise resilience by focusing on businesses that pair modest risk profiles with sturdier metrics using the 68 resilient stocks with low risk scores.
- Hunt for under followed stories with solid fundamentals that have not attracted wide attention yet via the screener containing 25 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com